NRS 455 RS T3 CASE STUDY ANALYSIS OF
MR. D'S RENAL DISEASE AND DIABETES |
2026 UPDATE WITH COMPLETE SOLUTIONS.
120 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NRS 455 RS T3 CASE STUDY ANALYSIS OF MR. D'S RENAL DISEASE AND DIABETES | 2026 UPDATE
WITH COMPLETE SOLUTIONS.. It contains 120 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 120 Questions
Foundations - Application - NRS 455 RS T3 CASE Study Analysis OF MR D S Renal Disease AND
Diabetes 2026 Update WITH Complete Solutions Advanced Pathophysiology Pharmacology AND Clinical
Management IN Chronic Renal Disease AND Diabetes Mellitus Graduate Master OF Science IN Nursing /
Nurse Practitioner
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Pathophysiology OF Renal 1-20 Kidney Disease, Diabetic, Diabetes, Appropriate, Serum
Disease
Diabetes Mellitus 21-40 Kidney, Disease, Diabetic, Diabetes, Inhibitor
Management
Pharmacological 41-60 Kidney, Disease, Diabetic, Diabetes, Hyperkalemia
Interventions
Nutritional Considerations 61-80 Diabetes, Diabetic, Kidney Disease, Stage, Appropriate
Fluid AND Electrolyte 81-100 Diabetes, Kidney, Disease, Stage, Diabetic
Balance
Hemodialysis AND Peritoneal 101-120 Kidney, Disease, Diabetes, Diabetic, Appropriate
Dialysis
TOTAL 120 All questions include answers and detailed rationales
,Section A - Pathophysiology OF Renal Disease
Q1.
In the context of diabetic kidney disease, which pathophysiological mechanism most
directly explains the early development of glomerular hyperfiltration and subsequent
albuminuria?
A. Tubular atrophy leading to reduced B. Hyperglycemia-induced afferent arteriolar
sodium reabsorption and tubuloglomerular vasodilation exceeding efferent arteriolar
feedback activation vasoconstriction, increasing intraglomerular
pressure
C. Mesangial cell proliferation causing D. Podocyte effacement leading to impaired
capillary loop obliteration and reduced glomerular basement membrane charge
filtration surface area selectivity
Correct: B - Hyperglycemia-induced afferent arteriolar vasodilation exceeding efferent
arteriolar vasoconstriction, increasing intraglomerular pressure
Rationale:Early diabetic kidney disease is characterized by afferent arteriolar vasodilation
(due to hyperglycemia and local mediators) with relative efferent vasoconstriction (angiotensin
II), raising intraglomerular pressure and causing hyperfiltration. Tubular atrophy and
mesangial expansion occur later, while podocyte injury contributes to proteinuria but is not the
primary cause of hyperfiltration.
Q2.
A patient with type 2 diabetes and eGFR 28 mL/min/1.73 m² is currently on metformin
1000 mg twice daily. According to 2026 guidelines, what is the most appropriate
pharmacologic adjustment?
A. Continue metformin at the same dose but B. Reduce metformin to 500 mg twice daily
monitor renal function every 3 months and reassess in 3 months
C. Discontinue metformin and initiate insulin D. Switch to metformin extended-release to
glargine reduce gastrointestinal side effects
Correct: B - Reduce metformin to 500 mg twice daily and reassess in 3 months
Rationale:Metformin is contraindicated when eGFR <30 mL/min/1.73 m²; at eGFR 30-45,
continuation is possible with dose reduction (max 1000 mg/day) and close monitoring.
Therefore, reducing to 500 mg twice daily is appropriate. Continuing full dose, discontinuing
outright, or switching to ER does not align with guidelines.
Q3.
In a patient with diabetic kidney disease and heart failure with reduced ejection fraction,
which class of medication has been shown to reduce the composite risk of cardiovascular
Page 3
, Section A - Pathophysiology OF Renal Disease
death and heart failure hospitalization, and is recommended as first-line regardless of
glycemic status?
A. Dipeptidyl peptidase-4 (DPP-4) inhibitors B. Sodium-glucose cotransporter-2 (SGLT2)
inhibitors
C. Glucagon-like peptide-1 (GLP-1) receptor D. Insulin glargine
agonists
Correct: B - Sodium-glucose cotransporter-2 (SGLT2) inhibitors
Rationale:SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) have robust evidence for
reducing cardiovascular death and heart failure hospitalizations in patients with or without
diabetes, and are recommended in CKD and HFrEF. GLP-1 agonists reduce atherosclerotic
events but not heart failure hospitalizations to the same extent; DPP-4 inhibitors are neutral;
insulin does not confer these benefits.
Q4.
A 2026 case analysis of Mr. D reveals an eGFR of 22 mL/min/1.73 m² and serum potassium
5.6 mEq/L. Which combination of medications is most likely contributing to this
hyperkalemia?
A. Metformin and liraglutide B. Lisinopril and spironolactone
C. Empagliflozin and furosemide D. Insulin glargine and sitagliptin
Correct: B - Lisinopril and spironolactone
Rationale:Both ACE inhibitors (lisinopril) and mineralocorticoid receptor antagonists
(spironolactone) reduce aldosterone-mediated potassium excretion, and their combination in
advanced CKD markedly increases hyperkalemia risk. Metformin, liraglutide, empagliflozin,
furosemide, insulin, and sitagliptin do not have this additive effect.
Q5.
In a patient with type 2 diabetes and CKD stage G4, which of the following insulin
regimens is most appropriate to minimize the risk of hypoglycemia while achieving
glycemic control?
A. Premixed insulin 70/30 twice daily B. Basal insulin glargine once daily with
rapid-acting insulin at meals
C. Regular insulin sliding scale four times D. Basal insulin detemir once daily, with
daily dose adjusted to fasting glucose
Correct: D - Basal insulin detemir once daily, with dose adjusted to fasting glucose
Page 4
MR. D'S RENAL DISEASE AND DIABETES |
2026 UPDATE WITH COMPLETE SOLUTIONS.
120 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NRS 455 RS T3 CASE STUDY ANALYSIS OF MR. D'S RENAL DISEASE AND DIABETES | 2026 UPDATE
WITH COMPLETE SOLUTIONS.. It contains 120 carefully selected questions that reflect the most current exam
content and testing strategies. Each question is accompanied by a correct answer and a detailed rationale that
explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 120 Questions
Foundations - Application - NRS 455 RS T3 CASE Study Analysis OF MR D S Renal Disease AND
Diabetes 2026 Update WITH Complete Solutions Advanced Pathophysiology Pharmacology AND Clinical
Management IN Chronic Renal Disease AND Diabetes Mellitus Graduate Master OF Science IN Nursing /
Nurse Practitioner
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Pathophysiology OF Renal 1-20 Kidney Disease, Diabetic, Diabetes, Appropriate, Serum
Disease
Diabetes Mellitus 21-40 Kidney, Disease, Diabetic, Diabetes, Inhibitor
Management
Pharmacological 41-60 Kidney, Disease, Diabetic, Diabetes, Hyperkalemia
Interventions
Nutritional Considerations 61-80 Diabetes, Diabetic, Kidney Disease, Stage, Appropriate
Fluid AND Electrolyte 81-100 Diabetes, Kidney, Disease, Stage, Diabetic
Balance
Hemodialysis AND Peritoneal 101-120 Kidney, Disease, Diabetes, Diabetic, Appropriate
Dialysis
TOTAL 120 All questions include answers and detailed rationales
,Section A - Pathophysiology OF Renal Disease
Q1.
In the context of diabetic kidney disease, which pathophysiological mechanism most
directly explains the early development of glomerular hyperfiltration and subsequent
albuminuria?
A. Tubular atrophy leading to reduced B. Hyperglycemia-induced afferent arteriolar
sodium reabsorption and tubuloglomerular vasodilation exceeding efferent arteriolar
feedback activation vasoconstriction, increasing intraglomerular
pressure
C. Mesangial cell proliferation causing D. Podocyte effacement leading to impaired
capillary loop obliteration and reduced glomerular basement membrane charge
filtration surface area selectivity
Correct: B - Hyperglycemia-induced afferent arteriolar vasodilation exceeding efferent
arteriolar vasoconstriction, increasing intraglomerular pressure
Rationale:Early diabetic kidney disease is characterized by afferent arteriolar vasodilation
(due to hyperglycemia and local mediators) with relative efferent vasoconstriction (angiotensin
II), raising intraglomerular pressure and causing hyperfiltration. Tubular atrophy and
mesangial expansion occur later, while podocyte injury contributes to proteinuria but is not the
primary cause of hyperfiltration.
Q2.
A patient with type 2 diabetes and eGFR 28 mL/min/1.73 m² is currently on metformin
1000 mg twice daily. According to 2026 guidelines, what is the most appropriate
pharmacologic adjustment?
A. Continue metformin at the same dose but B. Reduce metformin to 500 mg twice daily
monitor renal function every 3 months and reassess in 3 months
C. Discontinue metformin and initiate insulin D. Switch to metformin extended-release to
glargine reduce gastrointestinal side effects
Correct: B - Reduce metformin to 500 mg twice daily and reassess in 3 months
Rationale:Metformin is contraindicated when eGFR <30 mL/min/1.73 m²; at eGFR 30-45,
continuation is possible with dose reduction (max 1000 mg/day) and close monitoring.
Therefore, reducing to 500 mg twice daily is appropriate. Continuing full dose, discontinuing
outright, or switching to ER does not align with guidelines.
Q3.
In a patient with diabetic kidney disease and heart failure with reduced ejection fraction,
which class of medication has been shown to reduce the composite risk of cardiovascular
Page 3
, Section A - Pathophysiology OF Renal Disease
death and heart failure hospitalization, and is recommended as first-line regardless of
glycemic status?
A. Dipeptidyl peptidase-4 (DPP-4) inhibitors B. Sodium-glucose cotransporter-2 (SGLT2)
inhibitors
C. Glucagon-like peptide-1 (GLP-1) receptor D. Insulin glargine
agonists
Correct: B - Sodium-glucose cotransporter-2 (SGLT2) inhibitors
Rationale:SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) have robust evidence for
reducing cardiovascular death and heart failure hospitalizations in patients with or without
diabetes, and are recommended in CKD and HFrEF. GLP-1 agonists reduce atherosclerotic
events but not heart failure hospitalizations to the same extent; DPP-4 inhibitors are neutral;
insulin does not confer these benefits.
Q4.
A 2026 case analysis of Mr. D reveals an eGFR of 22 mL/min/1.73 m² and serum potassium
5.6 mEq/L. Which combination of medications is most likely contributing to this
hyperkalemia?
A. Metformin and liraglutide B. Lisinopril and spironolactone
C. Empagliflozin and furosemide D. Insulin glargine and sitagliptin
Correct: B - Lisinopril and spironolactone
Rationale:Both ACE inhibitors (lisinopril) and mineralocorticoid receptor antagonists
(spironolactone) reduce aldosterone-mediated potassium excretion, and their combination in
advanced CKD markedly increases hyperkalemia risk. Metformin, liraglutide, empagliflozin,
furosemide, insulin, and sitagliptin do not have this additive effect.
Q5.
In a patient with type 2 diabetes and CKD stage G4, which of the following insulin
regimens is most appropriate to minimize the risk of hypoglycemia while achieving
glycemic control?
A. Premixed insulin 70/30 twice daily B. Basal insulin glargine once daily with
rapid-acting insulin at meals
C. Regular insulin sliding scale four times D. Basal insulin detemir once daily, with
daily dose adjusted to fasting glucose
Correct: D - Basal insulin detemir once daily, with dose adjusted to fasting glucose
Page 4
